Aurinia PharmaceuticalsAUPH +0.06%81 PE Ratio (TTM) is 7.47 as of Jul. 08, 2026, which is 72% below its 10-year median of 26.45. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 271 Biotechnology companies, Aurinia Pharmaceuticals ranks better than 82.66% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-08), Aurinia Pharmaceuticals's share price is
$16.215.
Aurinia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.17. Therefore, Aurinia Pharmaceuticals's PE Ratio (TTM) for today is 7.47.
The historical rank and industry rank for Aurinia Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
AUPH'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 6.71 Med: 26.45 Max: 170.8
Current: 7.48
During the past 13 years, the highest PE Ratio (TTM) of Aurinia Pharmaceuticals was 170.80. The lowest was 6.71. And the median was 26.45.
AUPH's PE Ratio (TTM) is ranked better than 82.66% of 271
companies
in the Biotechnology industry
Industry Median: 27.53
vs AUPH: 7.48
During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 55.00% per year. The lowest was -287.60% per year. And the median was 4.90% per year.
Aurinia Pharmaceuticals (NAS:AUPH) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Aurinia Pharmaceuticals PE Ratio (TTM) Related Terms
Aurinia Pharmaceuticals PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AUPH vs KOD, ABCL, AGIO: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's PE Ratio (TTM) falls into.
Aurinia Pharmaceuticals PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Aurinia Pharmaceuticals's Share Price of today is $16.215.
Aurinia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Aurinia Pharmaceuticals (AUPH) has a PE Ratio (TTM) of 7.47 as of Jul. 08, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Aurinia Pharmaceuticals and its competitors. This is 72% below median its historical median of 26.45. Over the past decade, Aurinia Pharmaceuticals' PE Ratio (TTM) has ranged from 6.71 to 170.80. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #47 out of 271 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Aurinia Pharmaceuticals' PE Ratio (TTM) too high?
Aurinia Pharmaceuticals' current PE Ratio (TTM) of 7.47 is 72% below median its 10-year median of 26.45. Over the past 10 years, this metric has ranged from a low of 6.71 to a high of 170.80. The Biotechnology industry median PE Ratio (TTM) is 27.53. Aurinia Pharmaceuticals' value of 7.47 is 72.9% below this industry median. Based on the distribution chart, Aurinia Pharmaceuticals ranks #47 out of 271 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' PE Ratio (TTM) compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #47 out of 271 companies for PE Ratio (TTM). This places Aurinia Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 27.53. Aurinia Pharmaceuticals' value of 7.47 is 72.9% below this benchmark. Historically, Aurinia Pharmaceuticals' own PE Ratio (TTM) has ranged from 6.71 to 170.80 over the past decade. While the company's 10-year median is 26.45 vs. the industry median of 27.53, Aurinia Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.53, based on 271 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurinia Pharmaceuticals's current PE Ratio (TTM) of 7.47 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Aurinia Pharmaceuticals and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurinia Pharmaceuticals's current PE Ratio (TTM) is 7.47, which is 72% below median its own 10-year median of 26.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.02, compared to a current price of $16.22 — trading 15.7% above its estimated fair value. The current PE Ratio (TTM) is 7.47, which is 72% below median its 10-year median of 26.45 and 72.9% below the Biotechnology industry median of 27.53. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current PE Ratio (TTM) is 7.47 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.22 is trading 15.7% above its estimated GF Value™ of $14.02.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
PE Ratio (TTM): 7.47 (72% below median its 10-year median of 26.45)
GF Value™: $14.02 vs. price of $16.22 (15.7% above fair value)
Industry Position: 72.9% below the Biotechnology median (#47 of 271)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score
Get the complete analysis for AUPH
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
